REGN241213P810000
- 37.50
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,195
Regeneron Pharmaceuticals Analyst Ratings
B of A Securities Reinstates Underperform on Regeneron Pharmaceuticals, Announces $565 Price Target
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,186
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,186
Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $1,186 From $1,184, Maintains Overweight Rating
RBC Capital Remains a Buy on Regeneron (REGN)
Citi Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $895
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,110
Wolfe Research Initiates Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,150
Regeneron Pharma Initiated at Neutral by Citigroup
Regeneron Pharmaceuticals Analyst Ratings
Citi Upgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Raises Target Price to $895
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,175
Regeneron Pharma Is Maintained at Outperform by Oppenheimer
Regeneron Pharmaceuticals Analyst Ratings
Oppenheimer Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,000
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,126
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,110
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,195